Leadman(SZ:300289) Zheng Quan Zhi Xing·2025-08-01 16:36Group 1 - The company's stock price experienced a significant fluctuation, with a cumulative increase of 45.06% over two consecutive trading days (July 31, 2025, and August 1, 2025), which exceeds the 30% threshold for abnormal trading as per Shenzhen Stock Exchange regulations [1] - The company conducted a comprehensive self-examination and verified the situation with its controlling shareholders, actual controllers, and all board members regarding the abnormal stock price movement [1] - The company is in the preliminary planning stage of a major asset restructuring, intending to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash [1] Group 2 - The transaction is classified as a major asset restructuring under the relevant regulations, and the company is still in the early stages of planning, requiring further validation and negotiation of the transaction terms [1] - There are risks associated with the inability to complete necessary internal and external decision-making and approval processes for the transaction [1] - The company confirmed that there are no undisclosed significant matters related to the company or any other major matters in the planning stage [1]